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Human viruses known to be spread by sexual contact include herpes simplex viruses (HSV),
papillomaviruses (HPV), human immunodeficiency virus (HIV), hepatitis B virus, and cytome-
galovirus. Infections with the first three (HSV, HPV, and HIV) have reached epidemic
proportionsand poseglobal healthconcerns. Mostofwhatwe know aboutthesehumanpathogens
has been learned only recently, owing to the advent ofDNAtechnologies and advances in culture
techniques. In fact, our awareness ofone virally transmitted venereal disease, acquired immuno-
deficiency syndrome, dates to the early 1980s. This paper touches on various aspects of the
biology, pathogenesis, clinical manifestations, and, where applicable, oncogenicity of these
agents, as well as current treatments and vaccine initiatives.
INTRODUCTION
The introduction of antibiotics effectively dealt with the classic venereal diseases
gonorrhea and syphilis. The number of new cases of these diseases fell rapidly, and
many experts were lured into a false sense ofsecurity, going so far as to predict their
elimination. With more liberal attitudes and increased sexual freedom, coinciding with
the availability of birth control pills and antimicrobial therapy, the greatest fears of
sexual intimacy, pregnancy and venereal disease, were significantly reduced. In this
climate, there was a resurgence of sexually transmitted diseases, which included the
traditional venereal diseases as well as those of viral etiology. Epidemics of known
sexually transmitted viral agents, originally restricted to herpes simplex virus type 2
and, less frequently, type 1, now include the papillomaviruses, human immunodefi-
ciency virus, hepatitis B virus, and cytomegalovirus. What complicates this issue is the
multitude of virus types represented by some of these groups (i.e., the human
papillomaviruses). No longer viewed as infrequent and often minor problems, viruses
have added new dimensions in scale and complexity to our concepts of sexually
transmitted diseases. This paper is meant to review recent salient information
concerning the sexual transmission ofviruses and the consequences ofinfection.
HERPES SIMPLEX VIRUSES
Most ofthe human race eventually is infected with herpessimplexvirus (HSV) type
1 (HSV-1), type 2 (HSV-2), or both [1]. The viruses are spread by close personal
contact with someone shedding virus during social or sexual activities, although a
limited number of infections can be attributed to medical or dental procedures [2-4]
and fomites [5]. It has been said that HSV-1 and HSV-2 are almost perfect parasites
[1]. The viruses are able to infect exogenously, autoinfect (virus from a lesion in one
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area produces a lesion in another area), or superinfect (exogenous virus produces
lesions in a previously infected host) almost everyone, rarely killing their human host.
They can establish latent infections in the nervous system (the trigeminal ganglia in
the case of HSV-1 and the lumbosacral ganglia in the case of HSV-2), which persist
for life. Under the right conditions, the viruses can reactivate, producing recurrent
disease that may be clinical or asymptomatic, but is contagious nonetheless. In fact,
true primary, first-episode, and recurrent infections all can be transmitted to a new
host.
Asignificant percentage ofindividuals who are seropositive for HSV are unaware of
infection because it is mild and can easily be ignored or misdiagnosed. It has been
estimated that between 60 and 75 percentofprimary HSV infections aresymptomatic
[1]. Asymptomatic viral shedding has been reported in 2 to 9 percent of individuals
with oropharyngeal (type 1) infections and in 0.3 to 8 percent of individuals with
anogenital (type 2) infections [6,7]. These figures are probably much higher, however,
because the percentages represent infrequent samplings and because viral titers are
much lower in asymptomatic than in symptomatic infections.
In general, orolabial HSV-1 infections occur in childhood, HSV-2 anogenital
infections predominate with the onset of sexual activity during adolescence and early
adulthood, and new infections ofboth types occur at low rates frommidlifethrough old
age. HSV-1 infections of the mouth are the most common type of herpes simplex
infection. Although 500,000 new cases per year are estimated, the fact that many
orolabial infections are mild or misdiagnosed may greatly underestimate the true
number. In the United States, estimates of between 70,000,000 and 100,000,000
orofacial recurrences per year have been reported [1].
HSV-2 infectionsofthegenitals have been recognizedclinically sincethe 1700s [8],
have been of epidemic proportions since 1970, and continue to increase [9]. Private
office visits for genital herpes increased 1,500 percent between 1966 and 1984, and in
sexually transmitted disease clinics HSV-2 accounted for 4 percent ofvisits [10]. It is
now estimated that in the United States approximately half a million new cases of
genital herpes occur each year and that between 20 and 35 percent of white
middle-class Americans have HSV-2 genital infections [ 1].
As a rule of thumb, type 1 infections occur on the upper torso whereas type 2
infections occur below the waist. Because of changes in sexual mores and practices,
however, HSV- 1 infections of the genitals and HSV-2 infections ofthe orofacial area
are not uncommon. In fact, 20 to 25 percent of genital infections result from type 1
virus [ l1]. Corey [11] alsoobserved that type 2virus can be isolatedfrom 98 percentof
recurrent genital lesions. Although the clinical manifestations of genital HSV-1 and
HSV-2 infections arethesame, type 1diseasedoes not recur asoften (50 percentvs. 95
percent) as type 2 disease. In patients with the same herpetic type ofinfection at two
different anatomicsites(oral andgenital), infections recurred moreoften in thegenital
area than in the oral area regardless of herpesvirus type, although type 2 infections
recurred more often than type 1. This finding suggests that local factors (i.e., pH,
susceptible cell types, temperature, hormonal influences) play an important role in
virus reactivation, and that the virus interacts differently with the dorsal root ganglia
than with thetrigeminalganglia. Furthermore,despitehigh levelsofcell-mediatedand
humoral immunity, individuals with recurrent herpes are unable to eliminate latent
virus from the sensory ganglia. Thus, antibody-positive individuals are susceptible to
reinfection at a new site with the same or a different herpesvirus type.
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The herpes simplex viruses exhibit a structural and functional organization unlike
those of other viruses infecting eukaryotic cells [12]. The genome is a linear
double-stranded DNA molecule composed oftwo unique nucleotide sequences flanked
by inverted repeated sequences, which can invert to produce four different isomers.
Their icosahedral nucleocapsid contains the DNA which is surrounded by a lipid
bilayer envelope containing five or six viral glycoproteins that mediate attachment and
penetration into the host cell. There is significant homology between the HSV-1 and
HSV-2 genomes, and a number of the polypeptides specified by one type are
antigenically related to the other type [13].
A variety of approaches including cell transformation, seroepidemiologic studies,
isolation ofantigenicsequencesfrom human tumors, and induction oftumors in animal
models have been used to clarify the role of HSV-1 and HSV-2 in human neoplasia
[14]. Rather than clarifying virus participation, thesestudies have provided conflicting
information and fueled controversy for nearly 20 years. Numerous investigators have
detected sequences of the HSV genome in pre-neoplastic and neoplastic tissues.
Macnab [15] argues that the mechanisms involved in transformation of fibroblastic
cells in vitro are different from the effects of HSV on epithelial cells in vivo but that
some coded gene function is involved in tumorigenesis. Current thinking suggests that
HSV acts as a cofactor in the process of oncogenic transformation through its
involvement as a mutagen, an activator ofcellular genes, or a co-carcinogen.
PAPILLOMAVIRUS INFECTION
Human papillomaviruses (HPVs) are one ofthe most common sexually transmitted
viral infections in the United States and have shown a recent dramatic increase in
incidence: 460 percent during the 15 years spanning 1966 to 1981 [16]. Genital warts
have been recognized as venereal infections since Greek and Roman times; however,
their true etiology was not determined until 1949 upon visualization ofvirus particles
with the electron microscope [17], and their sexual transmission was not confirmed for
another five years [18]. Still, it took until 1971 to demonstrate that skin warts and
genital warts were different disease entities.
The HPVs remained largely uninvestigated because they could not be grown in cell
culture. Major breakthroughs became possible only with the application of DNA
technologies, which permitted isolation and sequencing oftheir genomes. Such studies
resulted in the identification of more than 50 different HPV types, as determined by
polynucleotide sequence homology and species specificity. The viruses can be distin-
guished by fundamental differences in tissue tropism, host range, and histopathologic
consequences. HPV isolates demonstrating greater than 50 percent DNA homology
with existing subtypes were designated subtypes, whereas those with less than 50
percent DNA homology were deemed new types. The number of distinct types and
subtypes has increased steadily, and it appears that each type preferentially infects a
specific anatomic site [19]. More than seven different types are known to infect the
genital tract ofmales and females [20]. It also has becomeevident that there is a broad
spectrum of epithelial disease manifestations associated with HPV infections, includ-
ing condylomas, intraepithelial neoplasias, and squamous carcinomas ofthe male and
female genital tract [21].
Although the papillomaviruses are classified as papovaviruses because of their
icosahedral virion capsids and covalently closed, supercoiled double-stranded DNA,
there are significant differences from other viruses in the group. Not only are their
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capsids larger and their chromosomes longer, but their genetic organization has little in
common with simian virus 40, polyomavirus, or the human JC and BK viruses. Broker
[21] suggests considering them a distinct and unique family. All wart viruses have a
similar appearance by electron microscopy. They show icosahedral symmetry and are
unenveloped. Their base composition of adenosine:thymine to guanosine:cytosine is
approximately 58 percent to 42 percent.
Condylomata acuminata of the cervix, a benign papillary epithelial proliferation,
and other similar genital lesions are usually associated with HPV types 6b and 11.
These two HPV types are also associated with low-grade dysplasias but appear to pose
little threat of progression to cancer; however, condylomata acuminata of the cervix
can indicate possible exposure to HPV types posing high risk ofcancer and in fact .20
percent of women with condylomata acuminata of the cervix also have cervical
intraepithelial neoplasia. In contrast, HPV types 16, 18, 30, 31, 33, 34, and 35 have
been linked to grade 2 and 3 intraepithelial neoplasias, primary invasive carcinomas,
and metastases [22-26]. HPV DNA has been detected in approximately 90 percent of
cervical squamous and adenocarcinomas examined [27], with HPV 16 detected most
frequently. HPV sequences have been detected in primary tumors as well as metastases
[28]. In addition, HPV 1, 2, 10, and 44 have been detected in anogenital condylomata
acuminata, HPV types 42 and 43 have been detected in cervical intraepithelial
neoplasia, and types 39 and 42 have been detected in bowenoid papulosis [29].
Approximately 90 percent ofcervical cancers and between 80 and 90 percent ofvulvar
and anogenital squamous cell carcinomas are attributable to oncogenic HPVs [Jenson
AB: personal communication]. Malignancies associated with HPV infections are held
responsible for 20 percent of cancer deaths in women [19], which reflects the high
mortality rates from cervical cancer in underdeveloped countries.
Like other sexually transmitted agents, i.e., Treponema palladum, Neisseria
gonorrhoeae, and herpes simplex viruses, genital warts types 6 and 11 also can afflict
the oral cavity. Basal cells of the epithelium appear to be the primary site of HPV
infection and serve as a reservoir for the viruses. Moreover, it appears that epithelial
cell differentiation is required for replication and transcription of viral DNA. Broker
[21] reports that wounding might be essential to permit access of HPV particles to the
basal cells and that wound healing may help establish HPV infection by increasing
basal cell division, stimulating capillary growth, and thus increasing blood supply at
the site of healing.
Due to the long lag time between initial infection and tumor development, it seems
that HPV infection alone is insufficient to induce cancer in an immunocompetent host.
Other cofactors such as use of tobacco products, infection with other microbial
pathogens (i.e., herpesviruses), and immunosuppression are probably involved [19].
The physical state of HPV 16 and 18 DNA shows alterations in associated tumors. In
invasive cancers, most of the viral DNA is integrated into the cellular chromosomes,
whereas in benign or pre-malignant lesions, HPV 16 and 18 DNA is extrachromo-
somal and present as episomes [30-32]; however, in cervical cancers associated with
HPV types 10, 11, and 33, the viral DNA exists in an extrachromosomal form,
indicating that integration is not necessary for malignancy. Many infections are
unrecognized and subclinical HPV infections are common [33], thus raising the risk of
transmission. In addition, standard Pap screening has a significant false-negative rate
for detecting viral infection.
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HUMAN IMMUNODEFICIENCY VIRUS
Unlike other sexually transmitted virus diseases, acquired immunodeficiency syn-
drome (AIDS) has a rather recent history, dating to the spring of 1981. From the
outset, epidemiologic data strongly indicated that AIDS was caused by an infectious
agent. The development ofAIDS in hemophiliacs and recipients ofblood transfusions
clearly pointed to a viral etiology. The discovery of the etiologic agent, termed
lymphadenopathy-associated virus (LAV), human T-cell lymphotropic virus type III
(HTLV-Ill), and AIDS-related virus (ARV), transpired in a very short time [34-36].
These terms have since given way to the internationally agreed-upon designation:
human immunodeficiency virus (HIV). It is now known that there is morethan a single
AIDS agent and that the HIV family appears to be a group ofagents [37].
HIV is classified as a retrovirus and has been placed in the lentivirus subgroup,
based on morphologic features, nucleotide sequences, and in vitro characteristics. By
electron microscopy, HIV has a lipid envelope, a dense cylindrical nucleoid containing
core proteins, genomic RNA, and reverse transcriptase. Yet HIV appears to be a
unique retrovirus [38]. Typical retroviruses contain gag, pol, and env genes. HIV,
however, possesses at least five extra genes that encode for the core proteins, reverse
transcriptase, and envelope proteins: tat and trs/art, which appear to be essential for
post-transcriptional or transcriptional regulation of HIV synthesis; sor and nef, which
encode for products concerned with infectivity and regulation, respectively; and "R,"
which has an unknown function. In contrast to other T-lymphotropic retroviruses,
HIVs do not appear to have immortalizing or transforming properties [37].
HIV can be transmitted by a number of routes involving close personal contact in
which infected cells or bodily fluids are introduced into the bloodstream ofa new host.
The most effective and possibly the only means of HIV transmission are through
sexual, blood-related (transfusions, sharing of intravenous drug instruments), prena-
tal, or perinatal exposure, or through breast milk [39]. Sexual transmission, specifi-
cally penetrative sexual intercourse, is the predominant mechanism of virus spread.
Both homosexual and heterosexual transmission of HIV can occur through contact
with semen or cervical secretions [40]. The sexual practice that poses the greatest risk
ofinfection is receptive anal intercourse, and this risk is amplified by large numbers of
partners [41]. It has been suggested that this increased risk is related to trauma and
tears in the rectal mucosa, allowing direct contact of infected semen with the
recipients' blood [42] and the fact that the rectal mucosa lacks secretory antibodies
present in other orifices. HIV transfer is not, however, always assured by high-risk
sexual practices [43] and, in fact, the rate of male-to-female transmission per
encounter has been estimated at 1 percent [40,44].
HIV infection can have a prolonged incubation period before the onset of clinical
disease. A median of seven years may elapse between the time of infection and
development of AIDS, with a range estimated between two and 15 years [45].
Although long asymptomatic periods are possible, pediatric AIDS patients and many
individuals with high-risk life styles have significantly shortened incubation periods.
HIV persists in infected individuals, who appear to be infectious for life. The fact
that the DNA transcribed from the HIV genome integrates into the host chromosome
after infection probably contributes to its prolonged persistence. Although T4 helper
cells are the prime target of HIV infection, monocytes and macrophages appear to be
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important alternative host cells. Because monocytes and macrophages are relatively
resistant to the cytolytic effect of HIV, they may be an important reservoir for HIV
and further contribute to virus persistence. Furthermore, because less than 0.01
percent of circulating lymphocytes express detectable HIV mRNA and infected
individuals have little cell-free virus [46], HIV appears to be latent or restricted in the
host and is not susceptible to immune clearance [38].
Perhaps one ofthe most important features ofHIV is its geneticvariability [47,48];
practically all isolates analyzed have distinct restriction maps. These variations have
pathogenetic importance since HIV can undergo genetic and functional changes
during incubation which could help thevirus evade host immune responses. Coffin [48]
reports that HIV isolates may vary in genome sequences by as much as 20 percent;
most of these "hypervariable" regions are located on the external envelope glycopro-
tein.
Depletion of T4 helper/inducer lymphocytes is the hallmark of AIDS. In fact, the
level of the T4 count is a useful predictor of clinical AIDS. Herpes zoster (in
individuals under 60) [49]; oral moniliasis; a combination ofany two ofthe following
clinical features: fever >100°F for 23 months, weight loss >10 percent or 215 pounds,
lymphadenopathy 23 months, diarrhea, fatigue, night sweats, plus any two of the
following laboratory abnormalities: helper T cells <400/mm3, helper to suppressor
ratio <1.0, leukothrombocytopenia/anemia, elevated serum globulins, depressed blas-
togenesis, anergy to skin tests; disappearance of antibodies to p24; and high titers of
antibody to cytomegalovirus frequently precede the development of AIDS by many
months [50,51].
HIV preferentially infects T4 helper cells by specific binding to the CD4 antigen
molecule, which is found on the cell membrane. Binding occurs when cellular CD4
interacts with an HIV envelope glycoprotein termed gpl20, allowing virus to enter the
cell [52]. Because HIV-infected cells manufacture gpl20 and carry it on the cell
membrane, healthy CD4-bearing cells can fuse to infected cells producing syncytia,
which, in turn, may bind to additional healthy cells. Thus a single HIV-infected cell
can fuse with as many as 50 cells, resulting in syncytia that cannot function and die
[52,53]. While CD4 is found primarily on T4 helper cells, other cells of the immune
system express the CD4 antigen (40 percent ofmonocytes; approximately 5 percent of
B cells) and are susceptible to infection [52].
After binding, HIV enters the susceptible cell and is uncoated. Thegenetic material
of the virus, RNA, is then transcribed into DNA by reverse transcripase, whereupon
the DNA is circularized and integrated into the host chromosome; however, much of
this DNA accumulates in the cytoplasm in a nonintegrated form. Activation of the
infected cells is necessary to complete the HIV replicative cycle. It is not known what
activates HIV, but there is speculation that co-infection with other microbial patho-
gens, such as cytomegalovirus, herpes simplex virus, and hepatitis B virus, may play a
role in activation of the virus [38] and that the interactions between cytomegalovirus
and HIV are bidirectional [54].
In addition to the almost complete ablation ofthe immune system, setting the stage
for multiple opportunistic infections, HIV also can infect the central nervous system
via macrophages, microglia, and derivative multinucleated cells [55,56]. Multiple
neurologic diseases (the AIDS dementia complex) involving both the central and
peripheral nervous system appear to be caused directly by HIV infection. Early after
infection (during seroconversion), individuals may experience a mononucleosis-like
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illness, with fever and acute or subacute meningitis [56,57]. Many patients (two-
thirds) go on to develop dementia, presenting as cognitive defects, memory loss,
seizures, and spasticity; myelopathy, presenting as paresthesias and painful dysesthe-
sias; and avariety ofdisorders that affect theperipheral nerves [56,57]. Upon autopsy,
80 to 90 percent ofAIDS patientsdemonstrateneuropathologicabnormalities [58,59].
As well, immunologicdepression appears tocontribute to thedevelopmentoflymphoid
malignanciesofthe B-cell system andKaposi sarcoma (KS) [60]. StudiesbyGalloand
co-workers [61] report that T cells infected with HIV produce a factor that supports
thegrowth ofKS cells in culture, suggesting that HIV may induce factors that dispose
AIDS patients to the development ofKS.
HEPATITIS B VIRUS AND CYTOMEGALOVIRUS
Two other viruses, hepatitis B virus and cytomegalovirus, bear mentioning as
sexually transmitted agents. Epidemiologic and serologic evidence indicates that
hepatitis B virus may be transmitted by heterosexual and homosexual intercourse.
Sexual partners of individuals positive for hepatitis B virus surface antigen (HBsAg)
can contract acute hepatitis B [62] or develop serologic evidence of hepatitis B virus
infection. An increased risk ofhepatitis B virus infection also has been noted in sexual
contacts ofindividuals with acute infection [63]. The most striking serologic evidence,
however, links hepatitis B virus transmission with homosexual sex practices. Increased
rates ofHBsAg correlate with duration ofhomosexual activity, high numbers ofsexual
partners, and anal sexual contact [64,65]. It is speculated that participation in
receptive anal intercourse damages the rectal mucosa, thereby facilitating virus
transfer. In addition, Schreeder and co-workers [65] detected HBsAg in stools of
homosexual men, strengthening the association of transfer of hepatitis B virus by
oral-anal sexual practices.
The replicative methods of hepatitis B virus show similarities to those of the
retroviruses in that a reverse transcriptase is required. Evidence indicates that
replication of hepatitis B virus is asymmetric [66,67]. Using RNA-dependent DNA
polymerase (reverse transcriptase), complete minus strands of DNA are synthesized
from a full-length RNA transcript copied from the complete DNA strand of the
hepatitis B virus genome. The second (or plus) strand of DNA is then transcribed
directly from the minus strand, producing the partially double-stranded genome ofthe
virus. In contrast to retroviruses, however, integration of the virus genome into the
cellular genome is not required for replication ofhepatitis B virus.
There are two stages of hepatitis B infection, a replicative phase and an integrated
phase. During the first, individuals are highly infectious and hepatic inflammation
progresses rapidly. In the second, the virus genome becomes integrated into the
genome ofthe host's liver cells, setting the stage for malignant transformation [68]. In
fact, there is significant evidence linking persistent infection with hepatitis B virus to
the development ofhepatocellular carcinoma [69].
Descriptions of"protozoan-like" cells in organs from a fetus and stillborn infant are
the first recorded documentation ofcytomegalovirus infections [70,71]. The virus has
been detected worldwide by epidemiologic studies, with the mode of transmission and
prevalence ofinfection related to age. Fifteen percent ofchildren acquire cytomegalo-
virus infections in utero or perinatally in the first few years of life [72]. By age 35,
approximately 50 percent of individuals show serologic evidence of previous infection
[73].
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The most common mode of transmission in adults is through intimate contact. It is
widely accepted that cytomegalovirus is sexually transmitted and this belief is
supported by the following known facts: (1) cytomegalovirus is not spread by close
nonsexual personal contact in adults [74]; (2) the percentageofseropositive individuals
is highest in patients attending sexually transmitted disease clinics; (3) cytomegalovi-
rus has been isolated from the cervix at a high rate in women with suspected venereal
disease; (4) male sexual contacts ofwomen with positive isolations ofcytomegalovirus
from the cervix are more likely to have cytomegalovirus in their semen; and (5) high
rates of infection with cytomegalovirus occur in promiscuous homosexual men [75].
Data suggest that the major route of transmission of cytomegalovirus infection in
homosexual men is exposure of the rectal mucosa to virus-infected semen through
passive anal intercourse [75].
Likeother herpesviruses, cytomegalovirus can persist in a latent statein the hostand
subsequently reactivate. It is morphologically indistinguishable from other herpesvi-
ruses and has the largest genome. Some ofthe viral proteins are capable oftrans mode
activity, which allows the virus to promote transcription of viral and cellular genes
[72].
Like herpes simplex virus, cytomegalovirus sequences have been detected in a small
percentage ofcervical neoplastic tissues [76] and, like herpes simplexvirus, cytomega-
lovirus most likely acts as a mutagen, activates cellular genes, or induces the synthesis
of host cell proteins not expressed by normal cells rather than playing a direct role in
carcinogenesis [15]. In this regard, cytomegalovirus may serve as a cofactor by
predisposing individuals to infection by HIV or by activating asymptomatic HIV
infection to progress to AIDS [54]. Indeed, high titers ofantibody to cytomegalovirus
are a predictor ofprogression to AIDS in HIV-seropositive individuals [51].
ANTIVIRALS AND VACCINES
Antivirals have demonstrated some short-term effectiveness against certain herpes
simplexvirus infections. Acyclovir treatment has been shown toshorten theduration of
mucocutaneous lesions due to HSV-1 and 2, and vidarabine has been used to decrease
the morbidity of herpes simplex encephalitis [77]. In an experimental system,
combined treatment of cells with human leukocyte interferon and nonoxynol 9 (a
non-ionic surfactant) synergistically inhibited HSV-2 and may have application as a
topical treatment for recurrent genital disease [78]; however, these antivirals do not
eliminate virus from latently infected ganglia. Topical 5-fluorouracil has shown
promise for treating resistant condylomas and preventing recurrences [79], as have
interferons [80] in combination with medical and surgical methods. A number of
experimental drugs have been used to treat AIDS patients, the most notable being
3'-azido-3'-deoxythymidine (AZT). AZT (a thymidine analog) is believed to suppress
HIV replication by inhibiting reverse transcriptase activity. The drug is able to cross
the blood-brain barrier, thereby penetrating the central nervous system. It appears
temporarily to reverse neurologic defects [81], facilitate weight gain, and lengthen
survival [82]. Present experimental AIDS drugs were designed to interrupt HIV
replication but, for the most part, have proven ineffective, toxic, or both.
Effective control will require prevention of virus infections at the portal of entry.
Thus far, this prevention has not been achieved by any antiviral vaccines. A vaccine
against herpes simplex virus must prevent disease, restrict or prevent asymptomatic
infection, and blockvirus latencyand reactivation. Traditional liveattenuatedvaccines
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TABLE 1
Problems Associated with Vaccine Strategies Against
Sexually Transmitted Viruses
1. Protected host environment
a. Integration into host genome
b. Latency in neurons
2. Host immunity does not clear infection
3. Viruses mutate, especially in glycoprotein moiety
4. Barrier at portal ofentry very difficult
5. Early access to target cell
6. Activated virus often spreads intracellularly
7. Tests for efficacy are complex
a. Selection oftest population difficult
b. Other variables (i.e., barrier devices) uncontrollable
c. Large number ofsubjects required, with long-term follow-up
pose long-term safety concerns, especially since herpes simplex viruses can transform
cells [83,84]. An experimental inactivated glycoprotein-subunit vaccineinitially tested
in 23 human subjects was shown to induce cell-mediated and humoral immune
responses to HSV-2 and to produce antibody responses to the glycoproteins of the
vaccine [85,86]. After follow-up for one year, four ofthe volunteers given this vaccine
acquired HSV infections: two demonstrated asymptomatic infections, and two had
atypical genital infections [87]. Because this trial was not a controlled efficacy study,
however, efficacy testing ofthis same vaccine in humans is now under way [88].
The task of developing a vaccine against AIDS is even more complex. A single
vaccine preparation is not likely to be effective against the many diverse HIV isolates.
In addition, HIV is primarily cell-associated, and humoral immune responses do not
neutralize the virus. Thus, traditional vaccines that build up natural host protection
would not be effective (Table 1). Furthermore, because HIV is a retrovirus and other
retroviruses have demonstrated oncogenic potential, development of a live-virus or
whole-inactivated virus vaccine iscontraindicated. The hope isthat recombinant DNA
technologies will provide the means to produce specific protective immunogens, but
unless they prevent entry into T cells, and monocytes and macrophages, they will fail
their mission. Most AIDS vaccine strategies are based on stimulating neutralizing
antibodies against the HIV envelope protein. Three candidate vaccines containing
viruses that have been genetically engineered to produce glycoprotein gpl60 (which
includes the HIV envelope glycoprotein gpl20) are in the first phase ofhuman testing.
There is, however, controversy as to whether antibody stimulation in itselfwill provide
protection, as vaccine trials in chimpanzees have not afforded protection [89,90], and
that cell-mediated immune responses may be required as well.
SUMMARY
Although the sexually transmitted viruses discussed, HSV, HPV, HIV, hepatitis B
virus, and cytomegalovirus, belong to different virus families and cause different
diseases, they do share some similarities. All are able to integrate their virus genetic
material intothe hostgenomeand causepersistent infections, many ofwhich cannot be
cleared by the host. All are, at a minimum, associated with the development of
neoplasias. HPVs and hepatitis B virus have been shown to play a causative role in
anogenital cancers and hepatocellular carcinoma, respectively.
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The advent and wide dissemination of HIV through high-risk populations have
forever altered the nature ofand attitudes toward sexually transmitted diseases. Once
established, infections with sexually transmitted viruses respond poorly to available
treatment, recur, and persist for life. In the case of HIV, infection is invariably fatal.
Other long-term consequences, especially in relationship to neoplasia and neurologic
disease, are cause for increasing concern. Traditional methods of control, early
diagnosis, treatment, tracing of sexual contacts, screening of high-risk groups, and
education are ineffective for the viral sexually transmitted diseases. Research is
currently directed at development of vaccines and more efficacious antiviral agents;
however, at present the best that can be offered is the possibility of modifying human
sexual behavior, historically a difficult prospect. Viruses, as an addition to traditional
sexually transmitted diseases, have had and will continue to have profound medical,
sociological, economic, and political impact for many years to come.
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